In recent developments, the dietary supplement industry is urging the Food and Drug Administration (FDA) to broaden the range of allowable ingredients in their products. This proposed change could pave the way for enhanced marketing of popular items such as peptides, probiotics, and various other wellness trends.
Last Friday, the FDA hosted a public meeting to review its established standards for dietary supplements. Discussions were centered on the potential to include ingredients that are not derived from traditional sources like food, vitamins, or herbs. In attendance were industry leaders, consumer advocates, and academics who provided diverse perspectives.
This meeting marks the first significant gathering since Robert F. Kennedy Jr. took office as the country’s health official last year. Kennedy has expressed his commitment to “end the war at the FDA” on dietary supplements, peptides, and other products that align with his Make America Healthy Again initiative.
The request for this meeting originated from the Natural Products Association, which has previously encountered disagreements with the FDA regarding new supplement ingredients. In a letter from January, the group highlighted the “cost and uncertainty that arise when regulatory expectations are unclear.”
Understanding the Regulatory Environment
According to FDA regulations, dietary supplements are classified within the food category, with most ingredients sourced from plants, herbs, and other elements found in the American diet. However, this requirement poses challenges to the industry, particularly as innovative wellness products now often include substances that have not been previously recognized as food.
For example, peptides—chains of amino acids that resemble drugs—are increasingly promoted by celebrities and influencers for their purported ability to enhance muscle growth and promote youthful appearances, despite a lack of solid scientific backing. While many specialty pharmacies and clinics offer them in injectable or IV formats, some supplement manufacturers have started incorporating these substances into capsules, gummies, and powders.
Legally speaking, such products may violate FDA regulations, a concern echoed by FDA attorneys. This also applies to some types of probiotics, which are marketed as beneficial for digestion and gut health.
Proponents of the industry contend that existing FDA law does not explicitly require all ingredients to originate from food sources. Robert Durkin, a previous FDA official and now a consultant for the industry, expressed hope that the meeting would lead the FDA to reassess what constitutes a dietary ingredient, potentially allowing for the inclusion of non-traditional dietary substances.
The Potential for Legal Action
If the agency remains resistant to redefining dietary ingredients, the industry may consider legal action. A recent Supreme Court decision in 2024 has limited federal regulators’ capacity to interpret laws and create regulations at their discretion.
Kennedy has publicly expressed his enthusiasm for peptides, sharing with podcast host Joe Rogan that he personally uses them for injury treatment. He also aims to relax FDA regulations surrounding the production of injectable peptides, which have faced stringent federal safety guidelines.
In support of Kennedy’s goals, figures like Gary Brecka, who markets peptide injections, patches, and nasal sprays, have become vocal proponents of these substances. Similarly, Dr. Mark Hyman, a close associate of Kennedy, markets a range of dietary supplements, including those containing peptides.
Additionally, two former health advisers from Kennedy’s presidential campaign have ties to the supplement industry. Calley Means, now a senior advisor at the Department of Health and Human Services, co-founded a platform that allows individuals to spend tax-free health dollars on wellness products. His sister, Dr. Casey Means, nominee for President Donald Trump’s surgeon general, has earned substantial income promoting a variety of supplements and probiotics.
The FDA’s Role
Unlike pharmaceuticals and other medical products, the FDA does not subject dietary supplements to the same rigorous review processes that confirm their safety and efficacy. In fact, the agency lacks a comprehensive list of all dietary supplements available in the market.
With approximately 100,000 different supplements currently in circulation, manufacturers bear the responsibility of ensuring their products are safe and accurately advertised. Claims that a supplement can treat specific illnesses or conditions are strictly prohibited.
The 1994 law granting the FDA oversight of dietary supplements exempted manufacturers from nutrition labeling requirements, allowing them to make less specific health claims. Instead, they can justify their products by stating that they support general well-being.
Concerns from Former Regulators
Some former regulators argue that this lenient approach invites problems. Mitch Zeller, who worked on FDA supplement issues during the 1990s, noted that it permitted unauthorized health claims. He highlighted that many supplement labels and advertisements are crafted to evade explicit drug or treatment claims.
Companies are permitted to assert that their products improve the structure or function of various body parts, such as enhancing bone strength. However, any claims made—whether general or specific—must include a disclaimer: “This statement has not been evaluated by the FDA.”
In closing, the ongoing discussions regarding the regulation of dietary supplements and their ingredients could significantly alter the landscape of the industry. As stakeholders push for broader acceptance of novel substances, the implications for consumer safety and product integrity remain to be seen.
The Key Takeaways for this article were generated with the assistance of large language models and reviewed by our editorial team. The article, itself, is solely human-written.
